Treatment with either of the two specific IRE1 endoribonuclease inhibitors exerts no effect on the kinase activity and autophoshorylation of IRE1 but only marked inhibition of XBP1 splicing and its downstream substrates, which strongly demonstrates that the IRE1-XBP1 axis is essential for MM cell survival and targeting this pathway may result in marked anti-tumor effects (120). The gene discussed is XBP1; the disease is neoplasm.